First AD

Second AD

Lung Cancer

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

The Evolving Treatment Landscape of Small Cell Lung Cancer

Peer Exchange

The panel shares clinical pearls for community oncologists treating small cell lung cancer.

Clinical Practice Pearls and the Future of SCLC

Overview of SCLC and Importance of Early Diagnosis

Use of the TNM Staging System in SCLC

Progress in the Treatment and Management of SCLC

Patient Profile 1: A 68-Year-Old Male with SCLC and Brain Metastases

Frontline Therapy for SCLC: The CASPIAN Trial of Durvalumab + Chemotherapy

Management of Adverse Events Associated with Durvalumab + Chemotherapy

IMpower 133 Trial and Patient Selection for Durvalumab + Chemotherapy vs Atezolizumab + Chemotherapy

Ongoing Trials and Real-World Studies in Frontline SCLC

Patient Profile 2: A 60-Year-Old Man with SCLC Progressing on First-Line Therapy

Second Line Treatment Options in SCLC and Selecting the Appropriate Therapy

Lurbinectedin for SCLC Treatment in the Second-Line Setting

Patient Profile 3: A 70-Year-Old Man with SCLC Receiving Chemotherapy in the Second-Line Setting

Choosing the Appropriate Treatment in the Second Line Setting in SCLC

Investigational Agents in SCLC in the Second Line Setting and Beyond